(0.27%) 5 105.50 points
(0.66%) 38 634 points
(0.56%) 17 749 points
(0.32%) $79.20
(0.10%) $2.04
(0.03%) $2 310.30
(-0.01%) $26.83
(1.12%) $973.40
(-0.14%) $0.931
(-0.49%) $10.94
(-0.19%) $0.796
(0.70%) $91.77
Live Chart Being Loaded With Signals
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia...
Stats | |
---|---|
今日成交量 | 49 720.00 |
平均成交量 | 34 619.00 |
市值 | 6.22M |
EPS | $0 ( 2024-04-02 ) |
下一个收益日期 | ( $-2.20 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.210 |
ATR14 | $0.0400 (1.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | King Thomas Braxton | Buy | 3 110 | Restricted stock units |
2024-04-18 | Patane Michael A | Buy | 3 556 | Restricted stock units |
2024-04-18 | Lee Catherine Chai-zon | Buy | 3 556 | Restricted stock units |
2024-04-18 | Mills Robert S | Buy | 4 667 | Restricted stock units |
2024-04-18 | Roberts Brandi | Buy | 5 333 | Restricted stock units |
INSIDER POWER |
---|
71.17 |
Last 95 transactions |
Buy: 4 806 950 | Sell: 2 066 322 |
音量 相关性
TFF Pharmaceuticals Inc 相关性 - 货币/商品
TFF Pharmaceuticals Inc 财务报表
Annual | 2023 |
营收: | $733 871 |
毛利润: | $231 391 (31.53 %) |
EPS: | $-11.85 |
FY | 2023 |
营收: | $733 871 |
毛利润: | $231 391 (31.53 %) |
EPS: | $-11.85 |
FY | 2022 |
营收: | $0 |
毛利润: | $-388 221 (0.00 %) |
EPS: | $-26.49 |
FY | 2021 |
营收: | $88.00 |
毛利润: | $88.16 (100.00 %) |
EPS: | $-0.00152 |
Financial Reports:
No articles found.
TFF Pharmaceuticals Inc
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。